Lilly's Foundayo wins U.K. approval, first for weight-loss pill outside United States
LONDON, Aug. 11. Eli Lilly's weight-loss pill Foundayo has received regulatory approval in the United Kingdom, the drug's first clearance outside the United States. The decision carries Lilly's competition with Novo Nordisk's Wegovy beyond a single market, opening a second front in a rivalry that until now has played out on American soil.
Key takeaways
- Eli Lilly's weight-loss pill Foundayo has received regulatory approval in the United Kingdom.
- The U.K. clearance is Foundayo's first approval outside the United States.
- Britain becomes the second country where Lilly holds regulatory clearance for the drug.
- Foundayo competes with Novo Nordisk's Wegovy in the weight-loss pill market, previously only in the U.S.
- Lilly described the U.K. approval as taking the weight-loss pill battle global.
LONDON, Aug. 11. Eli Lilly's weight-loss pill Foundayo has received regulatory approval in the United Kingdom, the drug's first clearance outside the United States. The decision carries Lilly's competition with Novo Nordisk's Wegovy beyond a single market, opening a second front in a rivalry that until now has played out on American soil.
Foundayo's first international approval
Foundayo and Novo Nordisk's Wegovy have competed in the United States as rival entries in the weight-loss pill category. Britain now becomes the second country where Lilly holds regulatory clearance for the drug. That is the transmission the U.K. decision represents: a domestic contest, extended.
The Novo Nordisk rivalry goes global
The weight-loss pill market has been defined by Lilly and Novo Nordisk pressing against each other in the U.S. Wegovy is Novo Nordisk's product in that space. With Foundayo now approved in the United Kingdom, both pills can compete on British ground. Lilly described the development as taking the weight-loss pill battle global, according to the announcement.
The source headline and summary provided no financial figures, regulatory body names, dates, pricing, or timelines. This piece reflects only the facts contained in the source.